AC	Adjuvant Chemotherapy
ADC	Antibody–Drug Conjugates
aaMVAC	Accelerated MVAC
Av	Avelumab
AZ	Atezolizumab
BC	Bladder Cancer
CG	Cisplatin and Gemcitabine
CI	Confidence Interval
CT	Chemotherapy
dd-MVAC	Dose Dense MVAC
DDR	DNA Damage Response
DFS	Disease-Free Survival
DUR	Durvalumab
EFS	Event-Free Survival
EV	Enfortumab Vedotin
FGFR	Fibroblast Growth Factor Receptor
HER2-ERBB2	Human Epidermal Growth Factor Receptor 2
HIF	Hipoxia Inducible Factor
HR	Hazard ratio
HRR	Homologous recombination repair
ICI	Immune checkpoint inhibitor
IDO	Indoleamine 2,3-dioxygenase
PARPi	Poly ADP-ribose Polymerase inhibitor
irAEs	Immune-Related Adverse Events
IT	Immunotherapy
KIR	Anti-Killer Cell Immunoglobulin-Like Receptor
LAG3	Lymphocyte-activation gene 3
LM	Linrodostat Mesylate
m	Month
MIBC	Muscle-Invasive Bladder Cancer
MVAC	Methotrexate, Vinblastine, Doxorubicin and Cisplatin
N	Nivolumab
NAC	Neoadjuvant Chemotherapy
NLR	Neutrophil/Lymphocyte Ratio
ORR	Overall Response Rate
pCR	Pathological complete response
PEM	Pembrolizumab
PGC	Paclitaxel, Gemcitabine and Cisplatin
PLND	Pelvic Lymph Node Dissection
PD-L1	Programmed Death Ligand 1
PFS	Progression-Free Survival
RC	Radical Cistectomy
RFS	Recurrence-Free Survival
UC	Urothelial Cancer
SAE	Serious Adverse Event
SG	Sacituzumab govitecan
TCGA	The Cancer Genome Atlas
TIM-3	T cell immunoglobulin and mucin-domain containing-3
TMB	The Mutation Burden
TRAEs	Treatment-Related Adverse Events
TROP-2	Tumor-associated calcium signal transducer 2
VEGF	Vascular endothelial growth factor
VH	Variant Histology
y	years